Study S001597

A Double-blind, Placebo-controlled Titration Study to Investigate the Tolerability, Safety and Pharmacodynamic Profile of a GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00460941
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 133
Start: 2007-04
Primary completion: 2008-01
Lead sponsor: Hoffmann-La Roche
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:Placebo; DRUG:Taspoglutide 20mg; DRUG:Taspoglutide 20mg-30mg; DRUG:Taspoglutide 20mg-40mg
Results posted: FALSE

Registered primary outcomes

Percentage of patients withdrawn because of gastrointestinal effects [Week 9]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021258	Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Ratner R, Diabetic medicine : a journal of the British Diabetic Association	2010	Randomized trial	PMID 20536952 DOI	cites ClinicalTrials.gov:NCT00460941; registry reference DERIVED:20536952